What is HC Wainwright’s Forecast for Kyntra Bio Q2 Earnings?

Kyntra Bio Inc (NASDAQ:KYNB) – Research analysts at HC Wainwright upped their Q2 2026 earnings estimates for Kyntra Bio in a report released on Tuesday, May 12th. HC Wainwright analyst M. Keller now forecasts that the company will earn ($3.62) per share for the quarter, up from their prior estimate of ($3.87). HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Kyntra Bio’s current full-year earnings is ($13.54) per share. HC Wainwright also issued estimates for Kyntra Bio’s Q3 2026 earnings at ($3.87) EPS, Q4 2026 earnings at ($4.15) EPS, FY2026 earnings at ($15.37) EPS, FY2027 earnings at ($7.57) EPS and FY2028 earnings at ($7.76) EPS.

Other analysts also recently issued reports about the stock. Zacks Research downgraded shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Wall Street Zen raised shares of Kyntra Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Weiss Ratings began coverage on shares of Kyntra Bio in a report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kyntra Bio currently has a consensus rating of “Hold”.

Kyntra Bio Price Performance

Shares of NASDAQ KYNB opened at $7.00 on Thursday. The business’s fifty day moving average price is $7.04. Kyntra Bio has a 1 year low of $4.85 and a 1 year high of $12.60. The stock has a market capitalization of $28.35 million, a P/E ratio of 0.17 and a beta of 1.03.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.